Shares of Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) have experienced a significant rally, rising more than 130% over the past 12 months as of mid-April 2026. This rebound follows a prolonged period of challenges for the Israel-based generic and specialty drugmaker, which has been navigating debt restructuring and legal settlements.
Financial analysts point to several factors supporting the stock's momentum. A primary catalyst is the anticipated launch of Teva's biosimilar version of Humira (adalimumab), a blockbuster autoimmune drug, expected in the U.S. market in 2026. Furthermore, the company's own branded drug, Austedo (deutetrabenazine) for movement disorders, continues to show strong sales growth. Teva's ongoing cost-cutting program and debt reduction efforts are also viewed positively by the market.
While the stock's dramatic rise has captured investor attention, analysts' price targets vary. Some firms have set targets around $40 per share, suggesting further upside from current levels, contingent on the successful execution of the company's strategic plans, particularly the Humira biosimilar launch and sustained growth of its key products.
